MARKET

NGEN

NGEN

Nervgen Pharma Corp
NASDAQ
3.810
+0.080
+2.14%
Opening 11:45 03/31 EDT
OPEN
3.800
PREV CLOSE
3.730
HIGH
3.870
LOW
3.710
VOLUME
78.97K
TURNOVER
--
52 WEEK HIGH
6.30
52 WEEK LOW
1.500
MARKET CAP
301.80M
P/E (TTM)
-14.6426
1D
5D
1M
3M
1Y
5Y
1D
NervGen Pharma FY GAAP EPS of -$0.61
Seeking Alpha · 2h ago
Press Release: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
Dow Jones · 4h ago
Press Release: NervGen Pharma Reports Full Year -2-
Dow Jones · 4h ago
NERVGEN PHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Reuters · 4h ago
Weekly Report: what happened at NGEN last week (0323-0327)?
Weekly Report · 1d ago
Weekly Report: what happened at NGEN last week (0316-0320)?
Weekly Report · 03/23 09:06
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade)
Seeking Alpha · 03/17 16:19
*News On NervGen Pharma Corp. (NGEN.V) Now Under NGEN
Dow Jones · 03/16 21:08
More
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Webull offers NervGen Pharma Corp stock information, including NASDAQ: NGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGEN stock methods without spending real money on the virtual paper trading platform.